(HealthDay News) — The Banff Automation System, based on an algorithm covering all classification rules and diagnostic scenarios, can improve diagnosis of kidney allograft rejection, according to a study published online in Nature Medicine.
Daniel Yoo, from the Université Paris Cité and the Paris Institute for Transplantation and Organ Regeneration, and colleagues developed a decision-support system to improve diagnosis of kidney allograft rejection, based on an algorithm covering all classification rules and diagnostic scenarios. Its ability to reclassify diagnoses for adult and pediatric kidney transplant recipients in three international multicentric cohorts and 2 large prospective clinical trials, including 4409 biopsies from 3054 patients, was tested.
The researchers found that the Banff Automation System reclassified 29.75% of 279 antibody-mediated rejection cases and 54.29% of 105 T cell-mediated rejection cases in the adult kidney transplant population, and reclassified 7.32% of 3239 biopsies diagnosed as nonrejection by pathologists as rejection. In the pediatric population, the reclassification rates were 30.77% of 26 and 30.77% of 39 for antibody- and T cell-mediated rejection, respectively. Reclassification of the initial diagnoses by the Banff Automation System was associated with improved risk stratification of long-term allograft outcomes.
“The results are unequivocal since more than 40% of diagnoses are corrected and reclassified by the machine,” a coauthor said in a statement. “This tool will enable better patient care as well as improve clinical trials and the development of immunosuppressive treatments.”
One author disclosed financial ties to Cibiltech, a software company not involved in the study.